StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of Navidea Biopharmaceuticals stock opened at $0.00 on Friday. The company has a market cap of $100,084.00, a P/E ratio of -0.02 and a beta of 1.46. Navidea Biopharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.13.
About Navidea Biopharmaceuticals
Recommended Stories
- Five stocks we like better than Navidea Biopharmaceuticals
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Best Stocks Under $5.00
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.